WARREN, N.J., Feb. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences:
TD Cowen 45th Annual Health Care 2025 Conference
Tuesday, March 4 at 11:10 a.m. ET
Barclays 27th Annual Global Healthcare Conference
Tuesday, March 11 at 12:30 p.m. ET
The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn, and X.
For More Information:
Investors:
Ellen Cavaleri
+1 (615) 618-6228
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Jeanine Clemente
+1 (908) 912-9406
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$47.95 |
| Daily Change: | -0.03 -0.06 |
| Daily Volume: | 268,215 |
| Market Cap: | US$3.800B |
May 06, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
